Zeo ScientifiXZEOX +0.71%50 Net Current Asset Value is $0.01 as of Apr. 2026, which is 100% below its 10-year median of 369.00. GuruFocus rates ZEOX with a GF Score™ of 50/100 and a GF Value™ of $2.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Zeo ScientifiX ranks worse than 99.26% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Zeo ScientifiX's net current asset value per share for the quarter that ended in Apr. 2026 was $0.01.
The historical rank and industry rank for Zeo ScientifiX's Net Current Asset Value or its related term are showing as below:
ZEOX'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 168 Med: 369 Max: 544
Current: 178.02
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Zeo ScientifiX was 544.00. The lowest was 168.00. And the median was 369.00.
ZEOX's Price-to-Net-Current-Asset-Value is ranked worse than 99.26% of 942
companies
in the Biotechnology industry
Industry Median: 4.875
vs ZEOX: 178.02
Zeo ScientifiX (OTCPK:ZEOX) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Zeo ScientifiX Net Current Asset Value Related Terms
Zeo ScientifiX Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZEOX vs JUNS, HOOK, LEXX: Net Current Asset Value Comparison
For the Biotechnology subindustry, Zeo ScientifiX's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.01 mean?
Zeo ScientifiX (ZEOX) has a Net Current Asset Value of $0.01 as of Apr. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Zeo ScientifiX and its competitors. This is 100% below median its historical median of 369.00. Over the past decade, Zeo ScientifiX's Net Current Asset Value has ranged from 168.00 to 544.00. According to the industry distribution chart, Zeo ScientifiX ranks #935 out of 942 companies in the Biotechnology industry, placing it in the top 99.3%.
Is Zeo ScientifiX's Net Current Asset Value too high?
Zeo ScientifiX's current Net Current Asset Value of $0.01 is 100% below median its 10-year median of 369.00. Over the past 10 years, this metric has ranged from a low of 168.00 to a high of 544.00. The Biotechnology industry median Net Current Asset Value is 4.88. Zeo ScientifiX's value of $0.01 is 99.8% below this industry median. Based on the distribution chart, Zeo ScientifiX ranks #935 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Net Current Asset Value compare to JUNS and HOOK?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #935 out of 942 companies for Net Current Asset Value. This places Zeo ScientifiX in the lower half of its industry. The industry median Net Current Asset Value is 4.88. Zeo ScientifiX's value of $0.01 is 99.8% below this benchmark. Historically, Zeo ScientifiX's own Net Current Asset Value has ranged from 168.00 to 544.00 over the past decade. While the company's 10-year median is 369.00 vs. the industry median of 4.88, Zeo ScientifiX has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.88, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current Net Current Asset Value of $0.01 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Zeo ScientifiX and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current Net Current Asset Value is $0.01, which is 100% below median its own 10-year median of 369.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.66, compared to a current price of $1.78 — trading 33.1% below its estimated fair value. The current Net Current Asset Value is $0.01, which is 100% below median its 10-year median of 369.00 and 99.8% below the Biotechnology industry median of 4.88. Zeo ScientifiX's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Net Current Asset Value is $0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.78 is trading 33.1% below its estimated GF Value™ of $2.66.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
Net Current Asset Value: $0.01 (100% below median its 10-year median of 369.00)
GF Value™: $2.66 vs. price of $1.78 (33.1% below fair value)
Industry Position: 99.8% below the Biotechnology median (#935 of 942)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
50GF Score
Get the complete analysis for ZEOX
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
